RxDoctor Payments Data

Sydnie Gamroth

Psychiatric/Mental Health · Rapid City, SDNPI 1992460539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Alkermes, Inc. at 30.0% of the total. 2025 is the largest year on record at $689, more than ten times the $42 reported in 2021.

$1,454in general payments, 2019–2025

Across 17 payments — averaging $85.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$437
  • Otsuka America Pharmaceutical, Inc.$269
  • Teva Pharmaceuticals USA, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$125
  • Axsome Therapeutics, Inc.$125
  • Vanda Pharmaceuticals Inc.$124
  • plus $249 from 3 others

What the payments were for

  • Food & beverage$1,454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,454 in reported general payments places this provider in the 75th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Medicare billing

Part B allowed, 2024
$16,050
Medicare patients
29
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate32$98,208
Aripiprazole56$533
Lurasidone Hcl15$432
Duloxetine Hcl36$409
Quetiapine Fumarate45$332
Buspirone Hcl40$299
Benztropine Mesylate17$265
Mirtazapine27$235
Venlafaxine Hcl ErVenlafaxine Hcl19$231
Lamotrigine11$196
Oxcarbazepine11$178
Risperidone11$166
Sertraline Hcl39$155
Hydroxyzine Hcl27$151
Trazodone Hcl24$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$91$98,20832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →